Annual Scientific Meeting of the American Pain Society 2006 - Medikamentöse Schmerzbehandlung - Ein Update

Die Häufigkeit von Schmerzen selbst hat in den letzten Jahren sicherlich nicht zugenommen, wohl aber die kritische Auseinandersetzung um deren Vermeidbarkeit. Immer mehr Stimmen fordern wirksamere Therapien von chronischen Schmerzen, aber auch von akuten Schmerzen etwa in der Folge von Operationen, wobei zur Bewertung des Schmerzes und des Erfolges der Therapie den Patienten selbst ein stärkeres Gewicht zukommt. Gleichzeitig stellt die Industrie weiterentwickelte Schmerzmedikationen bereit.

Although the frequency of pain has definitely not increased in recent years, there has been a greater amount of critical discussion about how to avoid it. There is an increasing demand for an effective treatment of chronic pain and also of acute pain subsequent to surgery, the patients themselves being a most important factor. The pharmaceutical industry actually presents improved pain-relief preparations.

Key Words

pain - treatment - opioids - ziconotid - duloxetine - pregabaline

Literatur

• 1 Aqua K. et al. .Oxymorphone immediate release for postsurgical abdominal pain: a single- and multiple-dose randomized, placebo-controlled, active-comparator trial. 25th Annual Scientific meeting of the American Pain Society, San Antonio, Texas 826 2006
• 2 Cziske R. Faktoren des Schmerzerlebens und ihre Messung: Revidierte mehrdimensionale Schmerzskala.  Diagnostica. 1983;  1 61-74
• 3 Fava M. et al. . The effect of Duloxetin on painful physical symptoms in depressed patients: do improvements in these symptoms result in higher remission rates?.  J Clin Psychiatry. 2004;  65 521-530
• 4 Gimbel JS, Richards P, Portenoy RK. Controlled-release oxycodone for pain in diabetic neuropathy: a randomized controlled trial.  Neurology. 2003;  60 927-34
• 5 Goldstein DJ. et al. . Duloxetine vs. placebo in patients with painful diabetic neuropathy.  Pain. 2005;  116 109-118
• 6 Griesing T. et al. . Efficacy, safety, and tolerability of pregabalin treatment for diabetic peripheral neuropathy: findings from 6 randomized controlled trials.  Diabetologia. 2005;  48 A351
• 7 Hanna M. The safety and efficacy of OROS hydromorphone in patients with chronic cancer pain. 25th Annual Scientific meeting of the American Pain Society, San Antonio, Texas 733 2006
• 8 Heading CE. Ziconotide.  Idrugs. 2001;  4 339-50
• 9 Hopp M. et al. .Influence of an addition of naloxone to prolonged release (PR) oxycodone on the analgesic efficacy - Results of a clinical study. Deutscher Schmerzkongress 2005, Poster 11.2, Bremen 2005
• 10 Lockhart E. Topical sterile lidocaine patch to reduce postoperative pain and decrease need for oral analgesics after inguinal herniorrhaphy. 25th Annual Scientific meeting of the American Pain Society, San Antonio, Texas. Poster 834 2006
• 11 Portenoy R. et al. .Pregabalin for painful diabetc peripheral neuropathy and postherpetic neuralgia: onset and duration of analgesia in combined analyses of clinical studies. 25th Annual Scientific meeting of the American Pain Society, San Antonio, Texas. Poster 777 2006
• 12 Raskin J. et al. .Duloxetine in the long-term management of diabetic peripheral neuropathic pain - results from three clinical trials. 25th Annual Scientific meeting of the American Pain Society, San Antonio, Texas. Poster 775 2006
• 13 Robinson M. et al. .Duloxetine efficacay on pain symptoms: an independent analgesic effect. 25th Annual Scientific meeting of the American Pain Society, San Antonio, Texas. Poster 728 2006
• 14 Sathyan G. et al. .Pharmacokinetics of OROS hydromorphone are dose proportional and minimally effected by food. 25th Annual Scientific meeting of the American Pain Society, San Antonio, Texas. Poster 796 2006
• 15 Schwenk W. et al. . Beschleunigte Frührehabilitation in der operativen Medizin: Fast-Track-Rehabilitation.  Deutsches Ärzteblatt. 2005;  102 1514
• 16 Stoker D. et al. .Rylomin (intranasal morphine), a non-invasive alternative to injectable morphine: characterization of analgesic properties and side effects in moderate-to-severe postsurgical pain. 25th Annual Scientific meeting of the American Pain Society, San Antonio, Texas. Poster 733 2006
• 17 Taylor D. et al. .A randomized, placebo-controlled study of fentanyl effervescent buccal tablets for relief of breakthrough pain in opioid-tolerant patients with cancer. 25th Annual Scientific meeting of the American Pain Society, San Antonio, Texas. Poster 733 2006
• 18 Viscusi E. et al. .Alvimopan, a novel peripherally acting mu-opioid receptor antagonist does not affect opioid-based centarlly mediated analgesai following surgery. 25th Annual Scientific meeting of the American Pain Society, San Antonio, Texas. Poster 763 2006
• 19 Webster L. et al. .Open-label study of fentanyl effervescent buccal tablets in patients with noncancer pain and breakthrough pain: patient preference assessment. 25th Annual Scientific meeting of the American Pain Society, San Antonio, Texas. Poster 733 2006
• 20 Webster L. et al. .Oxytrex has minimal physical dependence and improved safety vs. oxycodone in phase III clinical trial in low-back pain. 25th Annual Scientific meeting of the American Pain Society, San Antonio, Texas. Poster 799 2006
• 21 www.painineurope.com, NFO world group
• 22 Ziegler D. et al. . Treatment of symptomatic diabetic polyneuropathy with the antioxidant Alpha-Lipoic acid: a meta-analysis.  Diabetic Med. 2004;  21 114-121

Korrespondenzadresse: